Clinical Trial Update: JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial entry notes a Phase 1/2 study evaluating JY231 Injection for active systemic lupus erythematosus (SLE), currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• JY231 Injection

Snippet

Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Conditions: Systemic Lupus Erythematosus (SLE) | Phase 1, Phase 2 | Status: RECRUITING